High Retention on Weight-Loss Drugs Wegovy and Zepbound as Coverage Expands

A recent analysis of U.S. pharmacy claims shows that nearly two-thirds of patients who initiated treatment with the weight-loss drugs Wegovy or Zepbound remained on them a year later. The persistence rate signifies marked progress compared to previous analyses, indicating enhanced insurance coverage and better management by physicians.

In early 2024, 63% of patients who began using Wegovy or Zepbound continued their regimen for at least 12 months. This is a significant increase from past figures, with Wegovy rising from 40% in 2023, according to Prime Therapeutics' analysis. Co-author Patrick Gleason expressed astonishment at the persistence hike, viewing it as a significant shift in patient adherence.

The study did not delve into specific reasons patients discontinued the drugs, though issues such as affordability, insurance coverage loss, and side effects were noted. Experts suggest prolonged use is necessary for lasting health benefits, despite the initial high costs and uncertainties over future savings.

(With inputs from agencies.)